Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 3/20 | 0.33 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.33 |
| ▸ | TAB1 | Q15750 | 1/20 | 0.33 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.31 |
| ▸ | KDM5A | P29375 | 1/20 | 0.31 |
| ▸ | PDE9A | O76083 | 1/20 | 0.31 |
| ▸ | CTSS | P25774 | 2/20 | 0.30 |
| ▸ | JAK2 | O60674 | 2/20 | 0.30 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL4089024 | 1.00 | DGAT1 (0.33) | DGAT1MAP3K7TAB1PAK1KDM5A | |
| SCHEMBL101904 | 0.94 | KDM5A (0.33) | DGAT1MAP3K7TAB1PAK1KDM5A | |
| SCHEMBL101903 | 0.94 | KDM5A (0.33) | DGAT1MAP3K7TAB1PAK1KDM5A | |
| SCHEMBL101474 | 0.84 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL101473 | 0.84 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL30663349 | 0.84 | DGAT1 (0.32) | DGAT1 | |
| SCHEMBL130538 | 0.82 | ALK (0.31) | KDM5A | |
| SCHEMBL130539 | 0.82 | ALK (0.31) | KDM5A | |
| SCHEMBL101798 | 0.79 | ALK (0.32) | MAP3K7KDM5AJAK2JAK1 | |
| SCHEMBL101799 | 0.79 | ALK (0.32) | MAP3K7KDM5AJAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2013-05-30 | — | — | US | disclosed |
| US-8415362-B2 | Pyrazolyl substituted pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors | INCYTE CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2009-07-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137681-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | DGAT1 4526/4885MAP3K7 35/4885TAB1 654/4885 |
| US-20090181959-A1 | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK3, JAK1, JAK2 | DGAT1 4526/4885MAP3K7 35/4885TAB1 654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.